AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 326333 — intervention group
Group type: EXPERIMENTAL
Intervention: Right stay (discharge after fulfilling clinical criteria)
Number of subjects: 100
Study 326333 — intervention group
Group type: COMPARATOR
Intervention: Fixed stay (discharge at an arbitrary 10 days after surgery)
Number of subjects: 100
Study 31030165 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinitol (300 mg/d)
Number of subjects: 90
Study 31030165 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinitol (500 mg/d)
Number of subjects: 90
Study 31030165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27633932 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychotherapy (PPT) for 8 weeks
Number of subjects: 76
Study 27633932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 76
Study 25876832 — intervention group
Group type: EXPERIMENTAL
Intervention: CR nifedipine (80 mg per day; 40 mg BID)
Number of subjects: 0
Study 25885986 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 300 mcg
Number of subjects: 40
Study 25885986 — intervention group
Group type: COMPARATOR
Intervention: Oral metoprolol 50 mg
Number of subjects: 40
Study 21887489 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile idiopathic arthritis (JIA) group
Number of subjects: 52
Study 21887489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 19491298 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprolide plus estradiol (E(2))
Number of subjects: 42
Study 19491298 — intervention group
Group type: COMPARATOR
Intervention: leuprolide plus placebo
Number of subjects: 42
Study 17225162 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3480 (50 mg, 100 mg, 200 mg)
Number of subjects: 0
Study 17225162 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3480 (single dose from 2 to 320 mg)
Number of subjects: 0
Study 17225162 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3480 (50 mg, 200 mg)
Number of subjects: 0
Study 17225162 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3480 (200 mg)
Number of subjects: 0
Study 17225162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15189259 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS/PDA
Number of subjects: 169
Study 15189259 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS
Number of subjects: 169
Study 15189259 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA
Number of subjects: 169
Study 11472614 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF impregnated gauze (40 micrcog/cm2 of skin‐irradiated area, twice per day) in addition to steroid cream
Number of subjects: 61
Study 11472614 — intervention group
Group type: COMPARATOR
Intervention: Steroid cream
Number of subjects: 61
Study 11472614 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF impregnated gauze
Number of subjects: 61
Study 9543404 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of 23 specific cost-effective guidelines based on a patient's chief complaint
Number of subjects: 14000
Study 7828693 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol bolus dispersion
Number of subjects: 216
Study 7828693 — intervention group
Group type: COMPARATOR
Intervention: Conventional lung function tests (FEV1, MEF25, MEF50, MEF75)
Number of subjects: 216
Study 3126635 — intervention group
Group type: EXPERIMENTAL
Intervention: Deponit 10 patch (10 mg of nitroglycerin over 24 hours)
Number of subjects: 19
Study 3126635 — intervention group
Group type: EXPERIMENTAL
Intervention: Deponit 10 patch
Number of subjects: 19
Study 3126635 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 19
Study 31038430 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-preferred live music (PPLM)
Number of subjects: 35
Study 31038430 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 35
Study 29410558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercise
Number of subjects: 29
Study 29410558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling exercise
Number of subjects: 29
Study 29410558 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 27602880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) consisting of 12 individual 1-hour sessions administered weekly by trained clinicians
Number of subjects: 100
Study 27602880 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 100
Study 24981503 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured diabetes prevention intervention
Number of subjects: 0
Study 24981503 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22607160 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education programme with motivational maintenance via telephone and annual refresher sessions
Number of subjects: 44
Study 22607160 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 44
Study 22607160 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education programme
Number of subjects: 44
Study 19907724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) coated with salivary components
Number of subjects: 0
Study 19907724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) coated with SRCRP2
Number of subjects: 0
Study 19907724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) treatment
Number of subjects: 0
Study 19907724 — intervention group
Group type: EXPERIMENTAL
Intervention: HA dentifrice applied in vivo
Number of subjects: 0
Study 18640477 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 549
Study 15864232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy during index hospitalization
Number of subjects: 10288
Study 15864232 — intervention group
Group type: COMPARATOR
Intervention: No lipid-lowering therapy during index hospitalization
Number of subjects: 10288
Study 15864232 — intervention group
Group type: COMPARATOR
Intervention: Patients with prior history of hyperlipidemia not discharged on lipid-lowering therapy
Number of subjects: 10288
Study 15864232 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient lipid-lowering therapy
Number of subjects: 10288
Study 14578647 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy agents (e.g., fluorouracil, gemcitabine, taxanes, capecitabine)
Number of subjects: 0
Study 11275925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (abciximab and reduced-dose thrombolytic agent) with adjunctive PCI
Number of subjects: 410
Study 11275925 — intervention group
Group type: COMPARATOR
Intervention: Full-dose thrombolytic agent alone with adjunctive PCI
Number of subjects: 410
Study 11275925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (abciximab) with adjunctive PCI
Number of subjects: 410
Study 11275925 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (abciximab) without adjunctive PCI
Number of subjects: 410
Study 11275925 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy alone with adjunctive PCI
Number of subjects: 410
Study 11275925 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy alone without adjunctive PCI
Number of subjects: 410
Study 9249638 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic-acid-based bioabsorbable barrier (test treatment)
Number of subjects: 0
Study 9249638 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable ePTFE barrier (control treatment)
Number of subjects: 0
Study 9249638 — intervention group
Group type: COMPARATOR
Intervention: Safety data comparison
Number of subjects: 0
Study 8272333 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor (EGF)
Number of subjects: 2
Study 8272333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 2
Study 3427802 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracting (pulling) a tube from the tympanic membrane
Number of subjects: 0
Study 3427802 — intervention group
Group type: EXPERIMENTAL
Intervention: Excising (freshening) the edge of the defect at the time of removal
Number of subjects: 0
Study 3427802 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29594999 — intervention group
Group type: EXPERIMENTAL
Intervention: D55 light source
Number of subjects: 49
Study 29594999 — intervention group
Group type: COMPARATOR
Intervention: D65 light source
Number of subjects: 49
Study 26916287 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic neck pain (NP) group
Number of subjects: 77
Study 26916287 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic widespread pain (CWP) group
Number of subjects: 77
Study 26916287 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 77
Study 26250474 — intervention group
Group type: EXPERIMENTAL
Intervention: Alu DNA methylation levels; higher levels observed in blood samples taken 4 or more years before diagnosis.
Number of subjects: 1397
Study 26250474 — intervention group
Group type: EXPERIMENTAL
Intervention: Alu DNA methylation levels; evaluated for those diagnosed 2 years after blood draw.
Number of subjects: 1397
Study 26250474 — intervention group
Group type: EXPERIMENTAL
Intervention: Alu DNA methylation levels; evaluated for those diagnosed 3 years after blood draw.
Number of subjects: 1397
Study 26250474 — intervention group
Group type: EXPERIMENTAL
Intervention: Alu DNA methylation levels; evaluated for those diagnosed less than 2 years after blood draw.
Number of subjects: 1397
Study 26250474 — intervention group
Group type: EXPERIMENTAL
Intervention: LINE-1 DNA methylation levels; evaluated overall.
Number of subjects: 1397
Study 26250474 — intervention group
Group type: EXPERIMENTAL
Intervention: Alu DNA methylation levels; evaluated overall.
Number of subjects: 1397
Study 23887448 — intervention group
Group type: EXPERIMENTAL
Intervention: Nootropics and antioxidants (specifically phenotropil and mexidol)
Number of subjects: 75
Study 23887448 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant mexidol
Number of subjects: 75
Study 23887448 — intervention group
Group type: EXPERIMENTAL
Intervention: Nootropics (general)
Number of subjects: 75
Study 21070344 — intervention group
Group type: EXPERIMENTAL
Intervention: Programme-assessed treatment (elaborate feedback)
Number of subjects: 97
Study 21070344 — intervention group
Group type: COMPARATOR
Intervention: Student-assessed treatment (minimal feedback)
Number of subjects: 97
Study 21070344 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CAIs
Number of subjects: 97
Study 18439164 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced ECGs
Number of subjects: 30
Study 18439164 — intervention group
Group type: COMPARATOR
Intervention: Nonpaced ECGs
Number of subjects: 30
Study 16761129 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine
Number of subjects: 60
Study 16761129 — intervention group
Group type: COMPARATOR
Intervention: d,l-methamphetamine
Number of subjects: 60
Study 16761129 — intervention group
Group type: COMPARATOR
Intervention: d-methamphetamine
Number of subjects: 60
Study 14586363 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.1 mg, 0.2 mg, or 0.4 mg)
Number of subjects: 144
Study 14586363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 14586363 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 144
Study 10880803 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter
Number of subjects: 26
Study 10880803 — intervention group
Group type: EXPERIMENTAL
Intervention: Startle reflex
Number of subjects: 26
Study 10880803 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiospinal reflex
Number of subjects: 26
Study 8937366 — intervention group
Group type: EXPERIMENTAL
Intervention: Penthienate (5 mg, three times a day for 4 weeks)
Number of subjects: 43
Study 8937366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 8937366 — intervention group
Group type: COMPARATOR
Intervention: Propantheline (15 mg, three times a day for 4 weeks)
Number of subjects: 43
Study 31750405 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital care for malnourished children
Number of subjects: 1428
Study 31750405 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient care for malnourished children
Number of subjects: 1428
Study 31750405 — intervention group
Group type: COMPARATOR
Intervention: Comparison of recovery rates between HIV seropositive and seronegative children
Number of subjects: 1428
Study 31750405 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of care (QoC) assessment
Number of subjects: 1428
Study 31750405 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory approach to improve QoC
Number of subjects: 1428
Study 29485533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive interdisciplinary pain treatment
Number of subjects: 104
Study 26656776 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity-based intervention targeting childcare providers, including two 3-hour workshops and a training manual, with booster sessions over 6 months.
Number of subjects: 83
Study 26656776 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity-based intervention targeting childcare providers.
Number of subjects: 83
Study 26656776 — intervention group
Group type: COMPARATOR
Intervention: Control group implementing standard curriculum.
Number of subjects: 83
Study 24688087 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5) plus Pemetrexed (500 mg/m²)
Number of subjects: 20
Study 22306290 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts of support provision
Number of subjects: 0
Study 22306290 — intervention group
Group type: COMPARATOR
Intervention: Thoughts of support receipt
Number of subjects: 0
Study 22306290 — intervention group
Group type: COMPARATOR
Intervention: Non-supportive social contact
Number of subjects: 0
Study 18093716 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 0
Study 18093716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17145528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity‐modulated radiotherapy (IMRT)
Number of subjects: 51
Study 17145528 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 51
Study 12584508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical contralateral lateral glide mobilization
Number of subjects: 20
Study 12584508 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic ultrasound
Number of subjects: 20
Study 10632912 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 microgram.kg‐1
Number of subjects: 50
Study 10632912 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.4 mg.kg‐1
Number of subjects: 50
Study 9574347 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 50
Study 9574347 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 50
Study 8311533 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with steroids
Number of subjects: 74
Study 8311533 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory parameters and temporal artery histology
Number of subjects: 74
Study 2423803 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 44
Study 2423803 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 44
Study 29136115 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 326
Study 29136115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r)
Number of subjects: 326
Study 29136115 — intervention group
Group type: COMPARATOR
Intervention: cART-naive comparator group
Number of subjects: 326
Study 27098346 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training intervention
Number of subjects: 119
Study 24102912 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aerobic exercise training (CON)
Number of subjects: 43
Study 24102912 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval aerobic exercise training (INT)
Number of subjects: 43
Study 24102912 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 43
Study 22341744 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 every 21 days) plus best supportive care
Number of subjects: 539
Study 22341744 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 539
Study 20538959 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric prognosis statement (10% chance of surviving)
Number of subjects: 169
Study 20538959 — intervention group
Group type: COMPARATOR
Intervention: Qualitative prognosis statement (very unlikely to survive)
Number of subjects: 169
Study 18490790 — intervention group
Group type: EXPERIMENTAL
Intervention: team goal-setting
Number of subjects: 86
Study 18490790 — intervention group
Group type: COMPARATOR
Intervention: control condition
Number of subjects: 86
Study 16942452 — intervention group
Group type: EXPERIMENTAL
Intervention: Mime therapy for three months (including massage, relaxation, inhibition of synkinesis, and coordination and emotional expression exercises)
Number of subjects: 50
Study 16942452 — intervention group
Group type: EXPERIMENTAL
Intervention: Mime therapy for three months
Number of subjects: 50
Study 16942452 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 50
Study 12970808 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care
Number of subjects: 237
Study 12970808 — intervention group
Group type: COMPARATOR
Intervention: Telephone triage
Number of subjects: 237
Study 10735462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 5 microg/kg per min
Number of subjects: 36
Study 10735462 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume expansion with albumin 20% 15 ml/kg
Number of subjects: 36
Study 10735462 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 36
Study 9021321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan, 1.5% sodium lauryl sulfate (SLS), and diluted propylene glycol (PG) in water (1:8) with 0.5% zinc citrate
Number of subjects: 0
Study 9021321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan with 0.5% zinc citrate
Number of subjects: 0
Study 9021321 — intervention group
Group type: COMPARATOR
Intervention: Control (triclosan/ethanol)
Number of subjects: 0
Study 9021321 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan in either propylene glycol (PG) or copolymer/PG
Number of subjects: 0
Study 1392423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ANF(99‐126) (bolus 100 micrograms/kg, 30‐min infusion of 0.1 micrograms/kg.min)
Number of subjects: 10
Study 1392423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1392423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined releasing hormone administration
Number of subjects: 10
Study 3904233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for 2 years
Number of subjects: 1285
Study 3904233 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group with systemic therapy reserved until the time of relapse
Number of subjects: 1285
Study 29806520 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Clostridium butyricum combined with Bifidobacterium infantis)
Number of subjects: 67
Study 29806520 — intervention group
Group type: COMPARATOR
Intervention: No probiotics
Number of subjects: 67
Study 28800755 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic exercises combined with verbal stimulation
Number of subjects: 0
Study 28800755 — intervention group
Group type: COMPARATOR
Intervention: Basic exercises without verbal stimulation
Number of subjects: 0
Study 28800755 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional exercise training with verbal stimulation
Number of subjects: 0
Study 28800755 — intervention group
Group type: COMPARATOR
Intervention: Functional exercise training without verbal stimulation
Number of subjects: 0
Study 26386792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 7243
Study 26386792 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 7243
Study 26386792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel with PPI
Number of subjects: 7243
Study 26386792 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel with PPI
Number of subjects: 7243
Study 26386792 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel vs Clopidogrel
Number of subjects: 7243
Study 23959209 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 45
Study 23959209 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 45
Study 23959209 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training (CT)
Number of subjects: 45
Study 23959209 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 CHF patients)
Number of subjects: 45
Study 20580193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless double‐wedged tapered stem with alumina‐alumina bearing
Number of subjects: 848
Study 20580193 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene control group
Number of subjects: 848
Study 18815508 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorization Program (CP) training
Number of subjects: 35
Study 18815508 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 35
Study 17167974 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy without immunotherapy (OK-432 administration)
Number of subjects: 45
Study 17167974 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy with immunotherapy
Number of subjects: 45
Study 17167974 — intervention group
Group type: COMPARATOR
Intervention: Spleen preservation without immunotherapy
Number of subjects: 45
Study 17167974 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen preservation with immunotherapy
Number of subjects: 45
Study 12860257 — intervention group
Group type: EXPERIMENTAL
Intervention: CETi‐1 vaccine (250 mg)
Number of subjects: 36
Study 12860257 — intervention group
Group type: EXPERIMENTAL
Intervention: CETi‐1 vaccine (second injection)
Number of subjects: 36